Plasmocure™ - Mycoplasma Elimination Reagent

Alternative Mycoplasma Removal Agent

In very rare cases, mycoplasmas resistant to Plasmocin™ have been reported. To eradicate these mycoplasmas, InvivoGen has developed a new antimycoplasma agent called Plasmocure™.

Plasmocure™ combines two antibiotics that act through different mechanisms of action than those in Plasmocin™. A two-week treatment with Plasmocure™ was found sufficient to completely eliminate the mycoplasmas. A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated.

Specifications

Product concentration: 100 mg/ml

Elimination of mycoplasmas in two weeks (recommended concentration of 50 μg/ml)

Shipped at room temperature

Contents

Plasmocure™ is provided as a cell culture tested, sterile filtered solution at a concentration of 100 mg/ml.

Description

Plasmocure™ contains two bactericidal components belonging to different antibiotic families. They both act by inhibiting the protein synthesis but use distinct mechanisms. The first antibiotic binds to the 50S subunit of the ribosome and blocks the peptidyltransferase activity. The second antibiotic binds to the isoleucyl-tRNA synthetase and halts the incorporation of isoleucine into bacterial proteins. These two specific and separate targets are found only in mycoplasmas and Gram positive bacteria, and are completely absent in eukaryotic cells. The cytotoxicity of Plasmocure™ is low, however a slowdown of cell growth may be observed at high concentrations due to the inhibition of mitochondria respiration. At the end of the treatment, when Plasmocure™ is removed from the culture medium, the cells return rapidly to their normal growth rate.

Citations

Recent articles using InvivoGen Plasmocure™ - Mycoplasma Elimination Reagent

ORDERING

Plasmocure™

Cat. Codeant-pc
Unit Size100 mg (1 ml)
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".